AUSTIN, TX — June 16, 2025 — Dripping Springs Biotech announced today it has closed an $18 million Series B funding round, led by Austin-based Silverton Partners with participation from existing investor Healthios Capital. The company will deploy the capital to accelerate clinical development of its lead therapeutic candidate and expand its Austin-area operations. The funding arrives as Dripping Springs Biotech prepares to advance DSB-401, its flagship gene-editing therapy targeting rare metabolic disorders, into Phase 2 clinical trials later this year. The compound demonstrated statistically significant results in Phase 1 safety trials completed in March, with the company reporting no serious adverse events among 34 enrolled patients. "This round validates both our science and our team," said CEO Dr. Mara Hollis. "We built this company around the conviction that precision medicine can solve problems that conventional drug development has largely ignored. This capital gives us the runway to prove that in the clinic." Dripping Springs Biotech will use a portion of the proceeds to hire approximately 40 research and clinical staff over the next 18 months, growing its workforce to nearly 120 employees. The company also plans to expand its wet laboratory facility in the Austin suburb of Dripping Springs, adding roughly 12,000 square feet of research capacity. The raise brings the company's total funding to $31 million since its founding in 2020. **About Dripping Springs Biotech:** Dripping Springs Biotech is a clinical-stage biopharmaceutical company developing precision gene-editing therapies for rare and underserved metabolic diseases. Headquartered in Austin, TX, the company combines proprietary CRISPR-based technology with a patient-first development philosophy. For more information, visit www.drippingspringsbiotech.com. ---